Pronuclear Injection

This procedure comprises three days of injections of one DNA vector into fertilized C57Bl/6J oocytes and transfer of injected zygotes into pseudopregnant females. Demonstration of a successful screening strategy to identify transgenic founders is required prior to injections. Payment of this fee does not guarantee the generation of transgenic founders because of the variability in construct integration into the genome.

 

General Overview of the Process

  1. Consult with core facility director regarding construct design.
  2. Generate construct and develop screening assay to screen for transgenic founders.
  3. Purify construct and provide documentation of optimized screening assay.
  4. Core generates pronuclear-stage embryos, microinjects DNA transgene, and transfers zygotes into pseudopregnant female mice.
  5. Core provides investigator with tissue samples to genotype pups.
  6. Investigator genotypes pups.
  7. Transgenic founders are transferred to the investigator.
  8. Founders are bred to create a transgenic line.

Featured Research

Genome Study Suggests New Strategies for Understanding and Treating Pulmonary Fibrosis

In findings published online in Nature Genetics on April 14, 2013, researchers at National Jewish Health, the University of Colorado and several other institutions found a number of genes associated with host defense, cell-cell adhesion and DNA repair, which provide clues to possible mechanisms underlying this currently untreatable disease. Read more.

Faculty by Research

The discoveries made in the laboratories at National Jewish Health have a profound impact on the understanding and treatment of human disease.

Browse our Faculty by Area of Research.